Delcath Systems Inc (DCTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Delcath Systems Inc (DCTH) has a cash flow conversion efficiency ratio of 0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($857.00K) by net assets ($112.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Delcath Systems Inc for the company's overall valuation and market capitalisation.
Delcath Systems Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Delcath Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Delcath Systems Inc ranked by their cash flow conversion efficiency. Explore Delcath Systems Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tellgen Corp
SHE:300642
|
0.025x |
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
N/A |
|
Protec Co. Ltd
KQ:053610
|
0.015x |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
0.047x |
|
Somalogic Inc
NASDAQ:SLGC
|
-0.043x |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
0.399x |
|
Changsha Tongcheng Holdings Co Ltd
SHE:000419
|
0.084x |
|
Einhell Germany AG
F:EIN
|
0.099x |
Annual Cash Flow Conversion Efficiency for Delcath Systems Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Delcath Systems Inc from 1999 to 2025. View DCTH stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.22 Million | $22.52 Million | 0.202x | +174.50% |
| 2024-12-31 | $68.75 Million | $-18.68 Million | -0.272x | +86.28% |
| 2023-12-31 | $15.78 Million | $-31.25 Million | -1.981x | -146.51% |
| 2022-12-31 | $-5.86 Million | $-24.95 Million | 4.258x | +325.17% |
| 2021-12-31 | $11.95 Million | $-22.60 Million | -1.891x | -82.59% |
| 2020-12-31 | $22.08 Million | $-22.87 Million | -1.036x | -127.80% |
| 2019-12-31 | $-6.36 Million | $-23.69 Million | 3.726x | +277.88% |
| 2018-12-31 | $-14.94 Million | $-14.73 Million | 0.986x | +104.34% |
| 2017-12-31 | $678.00K | $-15.40 Million | -22.711x | -338.09% |
| 2016-12-31 | $-1.49 Million | $-14.21 Million | 9.539x | +599.66% |
| 2015-12-31 | $8.60 Million | $-16.42 Million | -1.909x | -122.74% |
| 2014-12-31 | $18.14 Million | $-15.55 Million | -0.857x | +24.35% |
| 2013-12-31 | $30.10 Million | $-34.10 Million | -1.133x | +54.67% |
| 2012-12-31 | $20.01 Million | $-50.01 Million | -2.499x | -74.57% |
| 2011-12-31 | $26.10 Million | $-37.37 Million | -1.432x | -72.88% |
| 2010-12-31 | $29.08 Million | $-24.08 Million | -0.828x | -88.06% |
| 2009-12-31 | $23.76 Million | $-10.46 Million | -0.440x | +33.15% |
| 2008-12-31 | $10.21 Million | $-6.72 Million | -0.659x | -94.31% |
| 2007-12-31 | $16.43 Million | $-5.57 Million | -0.339x | +70.19% |
| 2006-12-31 | $8.09 Million | $-9.20 Million | -1.137x | -374.44% |
| 2005-12-31 | $12.60 Million | $-3.02 Million | -0.240x | +44.79% |
| 2004-12-31 | $6.79 Million | $-2.95 Million | -0.434x | +55.57% |
| 2003-12-31 | $2.17 Million | $-2.12 Million | -0.977x | +10.20% |
| 2002-12-31 | $1.64 Million | $-1.78 Million | -1.088x | -55.01% |
| 2001-12-31 | $3.23 Million | $-2.27 Million | -0.702x | -852.96% |
| 2000-12-31 | $4.91 Million | $-361.26K | -0.074x | +96.69% |
| 1999-12-31 | $490.00K | $-1.09 Million | -2.224x | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more